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Parkinson’s disease is a neurodegenerative disorder characterized by motor and
non-motor disturbances. Various pathogenic pathways drive disease progression
including oxidative stress, mitochondrial dysfunction, α-synuclein aggregation and
impairment of protein degradation systems. Dysfunction of the ubiquitin-proteasome
system in the substantia nigra of Parkinson’s disease patients is believed to be one of the
causes of protein aggregation and cell death associated with this disorder. Lactacystin, a
potent inhibitor of the proteasome, was previously delivered to the nigrostriatal pathway
of rodents to model nigrostriatal degeneration. Although lactacystin-treated animals
develop parkinsonian motor impairment, it is currently unknown whether they also
develop non-motor symptoms characteristic of this disorder. In order to further describe
the proteasome inhibition model of Parkinson’s disease, we characterized the unilateral
lactacystin model, performed by stereotaxic injection of the toxin in the substantia nigra of
mice. We studied the degree of neurodegeneration and the behavioral phenotype 1 and
3 weeks after lactacystin lesion both in terms of motor impairment, as well as non-motor
symptoms. We report that unilateral administration of 3µg lactacystin to the substantia
nigra of mice leads to partial (∼40%) dopaminergic cell loss and concurrent striatal
dopamine depletion, accompanied by increased expression of Ser129-phosphorylated
α-synuclein. Behavioral characterization of the model revealed parkinsonian motor
impairment, as well as signs of non-motor disturbances resembling early stage
Parkinson’s disease including sensitive and somatosensory deficits, anxiety-like behavior,
and perseverative behavior. The consistent finding of good face validity, together with
relevant construct validity, warrant a further evaluation of proteasome inhibition models
of Parkinson’s disease in pre-clinical research and validation of therapeutic targets.
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Introduction
Parkinson’s disease (PD) is an age-related neurodegenerative
disorder affecting 1% of the world-wide population (Massano
and Bhatia, 2012). The main symptoms of PD are motor-related,
with the cardinal features of bradykinesia, motor rigidity, and
rest tremor forming the basis of the neurological classification
of this disorder. These typical motor disturbances are believed
to be the manifestation of degeneration of dopamine (DA)
producing neurons of the Substantia Nigra (SN) pars compacta
(SNc) that project to the striatum. Furthermore, Lewy bodies,
protein aggregates highly enriched in the presynaptic protein
α-synuclein (Spillantini et al., 1997), are a pathological hall-
mark of this disorder, and it is currently believed that protein
aggregation makes an important contribution to the progressive
neurodegeneration observed in PD (McNaught and Olanow,
2006). Interestingly, ∼90% of α-synuclein in Lewy bodies is
phosphorylated at Ser129 (Fujiwara et al., 2002; Anderson
et al., 2006), indicating a potentially important role of this
post-translational modification in the formation of Lewy bodies
and cell death processes observed in PD.
Although significant effort has been invested in developing
strategies to stop disease progression, the current management
of PD still relies on symptomatic treatment with DA replacement
strategies. These approaches can be beneficial in the first years
after diagnosis, however the relentlessly progressive nature of PD
makes them less efficient in controlling the disease, and can be
the cause of disabling drug-induced side-effects (Schapira, 2009).
The failure to achieve neuroprotection in PD can stem from var-
ious causes, however one explanation for the inability to success-
fully translate positive pre-clinical findings could be the limited
diversity of animal models used (Jenner, 2008).
Proteasomal dysfunction has recently emerged as potential
contributor to cell death in PD (Lim, 2007; Ebrahimi-Fakhari
et al., 2012). Post-mortem data obtained from sporadic PD
patients demonstrate a decrease in all three catalytic activities
of the 20S proteasome (McNaught and Jenner, 2001; McNaught
et al., 2003; Tofaris et al., 2003), together with decreased expres-
sion of various 26S proteasome subunits (McNaught et al., 2002a;
Grunblatt et al., 2004; Bukhatwa et al., 2010). Interestingly, these
structural and functional defects in the 26/20S proteasomes
seem to be specific for the SNc, and do not occur in other brain
regions such as the striatum, or various cortical regions, where
neuronal loss is not observed (Furukawa et al., 2002; McNaught
et al., 2003; Tofaris et al., 2003). A dysfunctional proteasome
system can lead to aberrant protein turnover, and build-up
of damaged or misfolded proteins, and as such be one of the
causes of the protein aggregation and neuronal death observed
in PD (McNaught et al., 2001; Olanow and McNaught, 2006;
Ebrahimi-Fakhari et al., 2012). Consistent with this hypothesis,
local administration of lactacystin (LAC), a selective and potent
proteasomal inhibitor, leads to nigrostriatal DA-ergic cell death
when applied to the SNc of rats (McNaught et al., 2002b; Vernon
et al., 2010; Mackey et al., 2013; Pienaar et al., 2015) or the medial
forebrain bundle of mice (Xie et al., 2010). Furthermore, LAC
models consistently demonstrate the presence of α-synuclein
pathology (McNaught et al., 2002b; Fornai et al., 2003; Miwa
et al., 2005; Vernon et al., 2010, 2011; Xie et al., 2010; Mackey
et al., 2013; Pienaar et al., 2015), a feature difficult to reproduce
in toxin-based models of sporadic PD.
Besides motor symptomatology, PD patients also present a
series of non-motor symptoms, such as anxiety, depression,
somatosensory dysfunction, or cognitive impairment (Chaud-
huri and Schapira, 2009; Martinez-Martin and Damian, 2010;
Conte et al., 2013) that have a significant impact on the quality
of life (Martinez-Martin, 2011; Hinnell et al., 2012). Despite the
important burden of non-motor symptoms in PD, they remain
largely under-researched (Jain and Goldstein, 2012). While LAC-
treated rats and mice develop parkinsonian motor impairment
(Vernon et al., 2010, 2011; Xie et al., 2010; Mackey et al., 2013;
Konieczny et al., 2014; Pienaar et al., 2015), it is currently
unknown whether proteasomal inhibition models can be used to
study non-motor symptoms in PD.
In the current study we further characterized the unilateral
LACmodel of PD, performed by stereotaxic injection of the toxin
in the SNc of mice. We studied pathological changes by investi-
gating the degree of nigrostriatal DA-ergic degeneration, as well
as potential changes in α-synuclein and Ser129-phosphorylated
(S129-P) α-synuclein expression, at 1 and 3 weeks post-lesion.
Furthermore, we characterized the behavioral phenotype after
LAC lesion both in terms of motor impairment, and non-
motor symptoms, with specific emphasis on somatosensory dys-
function, anxiety- and depressive-like symptoms, and cognitive
impairment.
Materials and Methods
Animals
This study was performed onmale C57BL/6J mice (Charles River
Laboratories, France), 12-14 weeks of age at lesion. Mice were
group-housed (2-6 mice per cage) under standardized condi-
tions (25◦C, 10/14 h dark/light cycle), with free access to food
and water. Studies were performed according to national guide-
lines on animal experimentation and were approved by the Eth-
ical Committee for Animal Experimentation of the Faculty of
Medicine and Pharmacy of the Vrije Universiteit Brussel. The
results are reported in accordance with the ARRIVE guidelines
for reporting experiments involving animals (Kilkenny et al.,
2010).
Stereotaxic Surgery
Mice were anesthetized with a mixture of ketamine (100mg/kg
i.p.; Ketamine 1000 Ceva, Ceva Sante Animale, Brussels, Bel-
gium) and xylazine (10mg/kg i.p.; Rompun 2%, Bayer N.V.,
Brussels, Belgium), and positioned in a Kopf Model 963 Ultra
Precise Small Animal Stereotaxic Frame, with a mouse adap-
tor (David Kopf Instruments, California, USA). The skull was
exposed, and a small hole was made through the skull above the
left SNc. A volume of 1.5µL LAC 2µg/µL was injected into the
left SNc at the following coordinates: AP -3.0, LM -1.0, DV -
4.5 from bregma, according to the atlas of Paxinos and Franklin
(Paxinos and Franklin, 2007). LAC solutions were prepared by
dissolving 50µg LAC (Cayman Chemicals, Michigan, USA) in
25µL NaCl 0.9%. In order to minimize lesion variability due to
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degradation of the toxin ex vivo which can yield an inactive LAC
analog (Dick et al., 1996), fresh LAC solutions were prepared for
every four mice, and immediately stored on ice. Control sham-
operated mice received the same volume of vehicle (NaCl 0.9%),
at the same coordinates. To minimize unspecific tissue damage,
microinjections were performed using a 10µL Model 1701 RN
Neuros Syringe (Hamilton Company, Reno, USA), at a flow rate
of 0.5µL/min. After injection, the syringe was left in place for
an additional 5min, and then slowly removed. At the end of the
surgery, the skin was sutured, and mice received 4mg/kg keto-
profen i.p. (Ketofen,Merial, Brussels, Belgium) for post-operative
analgesia.
Neurobehavioral Assessment
At 1 and 3 weeks after LAC administration, mice were inves-
tigated in a variety of motor and non-motor based paradigms.
Behavioral assessment was performed between 9:00 a.m. and 6:00
p.m. (during the light phase), with alternate testing of sham- and
LAC-treated mice to ensure evaluation of both treatment groups
during the same time of the day. For tests requiring real-time
behavioral scoring (nest building test, adhesive removal test),
blinding for treatment condition was ensured by the presence of
an additional researcher unaware of the test order during evalu-
ation. For tests integrated off-line (cylinder test, light/dark test,
tail suspension test), the acquired video files were integrated in a
blinded manner. For the remaining tests (rotarod, and open field
tests), blinding for treatment was ensured by employing objec-
tive and automated integration systems (TSE RotarRod Systems,
and Noldus Ethovision respectively). For each behavioral test,
mice were acclimatized to the testing room at least 1 h prior to
assessment.
Rotarod Test
Motor function was investigated using an accelerating rotarod
system (TSE RotaRod Advanced, TSE Systems). Prior to surgery,
mice were trained for 5min at a constant speed of 5 rpm. During
this initial training phase, mice were placed immediately back on
the rod after falling, allowing them to get familiarized to the test.
In the second phase of training, mice underwent 3 repeated tri-
als of 1min at a fixed speed of 5 rpm, with 3min of rest between
trials. For testing the rotarod performance at baseline and after
lesion, mice underwent 5 repeated trials that started at constant
speed of 5 rpm for 30 s, and continued with a 5–25 rpm accelerat-
ing protocol during 200 s, leading to a maximum total rod time of
230 s. Mice were allowed 3min of rest between trials. The mean
of the 5 test trials underwent statistical analysis.
Cylinder Test
Forelimb akinesia and somatosensory asymmetry were investi-
gated in the cylinder test. In this behavioral paradigm, mice are
placed in a glass cylinder (10 cm diameter, and 21 cm height),
with their motor activity video-recorded during 3min. The
cylinder was placed next to 3 mirrors to allow visualization
of the movement from all angles. Subsequent analysis of the
recordings reveals asymmetry in forelimb use upon performing
weight-bearing supporting contacts with the cylinder walls. We
also evaluated thigmotactic scanning behavior, by calculating the
amount of time spent scanning the cylinder walls with the ipsilat-
eral side of the body compared to the contralateral side. Scanning
behavior was considered when the mouse was actively exploring
the cylinder wall, sniffing or performing head elongations in the
direction of the wall.
Adhesive Removal Test
Sensorimotor performance was assessed using the adhesive
removal test, as described previously (Bouet et al., 2009). After
mice were habituated to a transparent test box for 60 s, small
adhesive strips (0.3×0.4 cm) were taped on the plantar surface of
both forelimbs, by applying equal pressure. Next, the mice were
placed back in the test box. Two parameters were counted: time-
to-contact, defined as the time required for the mouse to sense
the presence of the adhesive (i.e., mouth to paw contact), indica-
tive of correct paw and mouth sensitivity, and time-to-remove,
defined as the time required to completely remove the adhesive
from the paw, reflecting sensorimotor performance (Bouet et al.,
2009). Furthermore, in order to obtain a more direct measure of
skilled and coordinated forelimb use after adhesive contact, we
subtracted time-to-contact from time-to-remove for each mouse
(remove-contact), a factor that can also be influenced by motiva-
tional aspects. If the mouse did not feel or remove an adhesive
during the trial, a maximum time of 120 s was given. Prior to
surgery, the mice were trained for 5 days by performing the test
in identical conditions as the test condition. The adhesive place-
ment order (left forepaw or right forepaw first) was alternated for
each day of training during the first 4 days, and randomized for
the last day of training, and for the test session.
Nest Building Test
Spontaneous motor performance, skilled forelimb use, and moti-
vational aspects of behavior were investigated using the nest
building test, as described previously (Deacon, 2006). In this
paradigm, mice were individually housed overnight in a non-
enriched cage, and challenged to build a nest starting from nest-
ing material in order to provide shelter and heat insulation. The
following morning, the quality of the nest was scored on a 0–5
scale, with 0 representing no nest, and 5 a perfect nest (Dea-
con, 2006). Furthermore, in order to provide a semi-independent
objective assay of nesting ability, the amount of nesting material
shredded was quantified, by weighing the complete nesting mate-
rial (one pressed cotton Nestlet™ square) before the test, and
weighing the untorn material at the end of the test.
Open-Field Test
For the open-field test, each mouse was monitored for 60min
in a Plexiglas box (60 × 60 cm; height 60 cm; center of the
arena defined as the central 40 × 40 cm zone), using an over-
head video tracking system connected to Ethovision 3.0 (Noldus).
At the end of a trial, various behavioral parameters were objec-
tively integrated by the software, including motor parameters
(distance traveled, velocity), as well as measures of persever-
ative motor behavior (turn angle, meander) and perseverative
thigmotaxis/anxiety-like behavior (time spent in center). Addi-
tionally, the thigmotactic scanning behavior during the first
5min of each trial was manually scored, by reviewing the
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recorded tracks in Ethovision, in a blinded manner. The thig-
motactic scanning preference (ipsilateral or contralateral to the
lesion) was analyzed by quantifying the time spent scanning the
open-field walls either using the ipsilateral side, or contralateral
side of the body.
Light/Dark Test
In the light/dark test, anxious behavior is investigated by com-
paring the innate exploratory activity of the mice with the prefer-
ence for an enclosed, safe shelter. Anxiety levels are revealed by
two parameters: time spent outside the shelter, and the latency
to exit the shelter. Additionally, using the set-up described by
Pogorelov et al., motor behavior parameters can be simultane-
ously reported, by analyzing the velocity of the mouse outside
the shelter (Pogorelov et al., 2007). At the beginning of the test,
each mouse starts in a dark shelter (30 × 30 cm; height 8.5 cm)
positioned in the corner of the open-field arena. Outside the shel-
ter, a brightly lit environment was created using three overhead
lamps, generating a light contrast (illuminance outside the shelter
700 lx, inside the shelter 0.5 lx). The behavior of the mouse dur-
ing a 5min trial was monitored using Ethovision. At the end of
the test, the recorded tracks were manually integrated to reveal
the time spent outside the shelter, as well as the latency to exit the
shelter.
Tail Suspension Test
Depressive-like behavior was investigated using the tail suspen-
sion test. In this “behavioral despair” paradigm, each mouse was
suspended by the tail, and videotaped during 5min. Integration
of the tail suspension videos was performed by manually count-
ing the total immobility time of each mouse. We also integrated
on the same video recordings the side preference (ipsilateral vs.
contralateral) when performing body swings during the escape-
oriented behavior. This parameter, also reported in the elevated
body swing test, is believed to give an indication of motor asym-
metry in unilateral DA depletion models (Roghani et al., 2002).
Body swings were quantified during the first minute of the tail
suspension test. A swing was counted whenever the mouse dis-
placed its body 30◦ from the vertical axis, and for another swing
to be counted the mouse must have returned first to its vertical
position. Mice that climbed their own tail during the test were
excluded from the study.
Neurochemical Analysis of Total DA and DOPAC
Content in the Striatum
After behavioral analyses, mice were sacrificed by cervical dis-
location. Brains were quickly removed, and the caudal part was
post-fixed for 3 days in freshly prepared 4% paraformaldehyde for
further use in immunohistochemistry (Sigma-Aldrich, Brussels,
Belgium). From the rostral part of the brain, striata were dissected
out on ice cold petri-dish, weighed, and homogenized in 400µL
antioxidant solution (0.05M HCl, 0.5% Na2S2O5, and 0.05%
Na2EDTA) containing 10 ng/100µl 3,4-dihydroxybenzylamine
as internal standard. The homogenate was centrifuged for 20min
at 10 000 × g at 4◦C, and the supernatants were immediately
diluted 1:5 in 0.5M acetic acid. TwentyµL of the resulting sample
dilution were analyzed for DA and DOPAC content on a narrow-
bore (C18 column, 5µm, 150× 2.1mm; Altima Grace, Lokeren,
Belgium) liquid chromatography system with an electrochem-
ical detector (Antec, Leiden, The Netherlands), as described
previously (Massie et al., 2011).
Immunohistochemistry for Detecting Tyrosine
Hydroxylase (TH) and Parvalbumin (PV)
Expressing Neurons
Forty µm vibratome sections were cut from the post-fixed cau-
dal part of the brain (Leica Microsystems, Germany), and stored
in serial order in 10mM PBS supplemented with 1.5mM sodium
azide at 4◦C. Nigral sections were selected to investigate the pres-
ence of TH and PV expressing neurons, using rabbit anti-TH
antibody (AB152; 1/2000; Millipore, Temecula, CA, USA) and
rabbit anti-PV antibody respectively (PV 25; 1/10000; Swant,
Bellinzona, Switzerland), and employing the ABC peroxidase
technique, as described previously (Massie et al., 2011). Photomi-
crographs were taken of the stained sections, and cell counts
were performed using ImageJ software (U.S. National Institutes
of Health, Bethesda, MD, USA). Total numbers of TH+ pro-
files in the SNc and VTA were counted blindly in 6 serial sec-
tions throughout the entire rostro-caudal extent of the SN (every
3 sections, 1 section was stained). Regional sub-analysis of the
VTA was performed by counting the number of TH+ profiles
in the lateral VTA (parabrachial pigmented nucleus, PBP) in 3
serial sections covering the peri-injection site (AP−2.92 to−3.08
from bregma). Similarly, the total number of SNr PV+ pro-
files was evaluated in 3 serial sections covering the peri-injection
site (AP -2.92 to -3.08 from bregma). The TH+ SN volume
was determined by stereological volume measurements based on
the Cavalieri method, on 4 serial TH stained sections covering
the rostro-caudal extent of the SN (every 5 sections, 1 section
was analyzed), using a computerized system (Stereo Investigator;
MicroBright-Field, Germany).
Immunodetection of α-Synuclein and S129-P
α-Synuclein
Mice in which we investigated the effect of LAC administra-
tion on α-synuclein and S129-P α-synuclein were sacrificed by
an overdose of pentobarbital (Nembutal, Ceva Sante Animale,
Brussels Belgium), and transcardially perfused with NaCl 0.9%
for 3min, followed by freshly depolymerized 4% paraformalde-
hyde in NaCl 0.9% supplemented with 0.85% H3PO4 (pH 7.42)
for an additional 6min. Next, brains were removed and post-
fixed in the same fixative overnight, rinsed in tap water for 24 h,
and stored in 10mM PBS supplemented with 1.5mM sodium
azide at 4◦C. Free-floating 40µm frontal sections were made
with a vibratome and stored in serial order in 10mM PBS sup-
plemented with 1.5mM sodium azide at 4◦C. Sections were
pre-treated with a mixture of 3% hydrogen peroxide and 10%
methanol in TBS for 10min followed by a blocking step of 1 h in
10% normal goat serum (DakoCytomation, Belgium) prepared
in TBS. Next, sections were incubated overnight with primary
antibody against α-synuclein (rabbit antibody, 1:5000, home-
made, Anke Van der Perren and Veerle Baekelandt, unpub-
lished) or S129-P α-synuclein (mouse monoclonal 1:5000, Elan
Pharmaceuticals, Ireland) in TBS-0.1% triton X-100, 10% goat
serum. As secondary antibody we used biotinylated anti-rabbit
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IgG for α-synuclein or biotinylated anti-mouse IgG for S129-P
α-synuclein (both 1:600, DakoCytomation), followed by incuba-
tion with streptavidin–horseradish peroxidase complex (1:1000,
DakoCytomation). Immunoreactivity was visualized using 3,3-
diaminobenzidine (0.4mg/ml, Sigma-Aldrich) as a chromogen.
After being rinsed and mounted, sections were cover slipped
using DPX mounting medium (Sigma-Aldrich). Photomicro-
graphs were taken of the stained sections, and densitometric anal-
yses were performed using ImageJ software in sections covering
the entire rostro-caudal extent of the SN. Optical density values
were calculated as [log265/mean gray value(SN)—log265/mean
gray value(background)], where SN was defined as the combined
SNc + SNr area, and normalization for background staining was
done considering the optical density of the ipsilateral cerebral
peduncle.
For fluorescent double staining, sections were rinsed three
times in PBS and then incubated overnight in PBS-0.1% triton
X-100, 10% donkey serum, and the following antibodies: mouse
anti-S129-P α-synuclein (1:1000, Elan Pharmaceuticals), rabbit
anti-TH (1:1000, Chemicon 152), rabbit anti-NeuN (1:1000, Mil-
lipore ABN78) and rabbit anti-GFAP (1:200, Dako, ZO344).
After three rinses in PBS-0.1% triton X-100 the sections were
incubated in the dark for 1 h in fluorochrome-conjugated sec-
ondary antibodies: donkey anti-mouse Alexa 488 (1:400, Molec-
ular Probes™, Invitrogen, Belgium) and donkey anti-rabbit
Alexa 647 (1:400, Molecular Probes™, Invitrogen). After being
rinsed in PBS and mounted, the sections were coverslipped with
mowiol. Fluorescent double staining was visualized by confocal
microscopy with an LSM 510 unit (Zeiss, Belgium).
Statistical Analysis
Data are expressed asmean± standard error of themean (s.e.m.).
Statistical analyses were performed using GraphPad Prism 4.0
software. For studying one variable within one group of animals
(Table 1), we used Student’s paired t-test. For all other analy-
ses, we employed the Two-Way ANOVA followed by Bonferroni
post-hoc test. The α-value was set at 0.05.
Results
Intranigral Injection of LAC Induces Acute and
Non-Progressive Nigrostriatal DA-ergic
Degeneration
Immunohistochemical analyses revealed that 3µg LAC admin-
istration led to significant loss of nigral TH expressing cells
in the lesioned SNc compared to the contralateral intact SNc
(Figures 1A,E,Table 1). Two-WayANOVA (with time and treat-
ment as factors) revealed a global effect of LAC lesion on loss
of nigral TH+ profiles [treatment factor: F(1, 18) = 31.12,
p < 0.001], with a significant decrease of ∼40% TH+ profiles
in the ipsilateral SNc at both 1 week (p < 0.01) and 3
weeks (p < 0.01) post-surgery. No significant changes could be
observed for TH+ profiles in the entire rostro-caudal extent of
the VTA [treatment factor: F(1, 18) = 0.21, p > 0.05; Table 1].
However, regional analyses of TH+ profiles in the lateral VTA
(PBP) revealed a local loss of∼30% TH+ profiles [treatment fac-
tor: F(1, 18) = 15.86, p < 0.001], at both 1 week (p < 0.05) and 3
weeks (p < 0.05) post-surgery, in sections covering the injection
site (AP−2.92 to−3.08 from bregma) (Figures 1B,E, Table 1).
Loss of nigral TH+ profiles translated into a significant loss
of DA content in the ipsilateral striatum compared to the con-
tralateral striatum (Figure 1C, Table 1). Similar as for the nigral
degeneration, Two-Way ANOVA revealed a global effect of LAC
lesion on striatal DA content [treatment factor: F(1, 20) = 32.54,
p < 0.001], with a significant decrease of ∼40% DA content in
the ipsilateral striatum observed at both 1 week (p < 0.01) and 3
weeks (p < 0.01) post-surgery. No significant changes could be
observed in striatal DOPAC/DA ratio at either 1 or 3 weeks after
LAC (Table 1), indicating no changes in DA turnover.
Intranigral administration of LAC caused a small, but signif-
icant atrophy of the ipsilateral SN, as evaluated using the Cava-
lieri probe estimator (Figures 1D,E, Table 1). Two-Way ANOVA
revealed a global effect of the lesion on the TH+ ipsilateral SN
volume [treatment factor: F(1, 22) = 30.00, p < 0.001], with a
significant decrease of ∼20% in volume observed at both 1 week
(p < 0.01) and 3 weeks (p < 0.001) post-surgery.
Finally, in order to investigate possible non-specific effects of
the lesion on GABA-ergic neurons located in the SNr, we com-
pared the number of PV-expressing neurons in the ipsilateral
SNr to the contralateral SNr on stained sections surrounding the
injection site (covering AP−2.92 to−3.08 from bregma).We did
not observe, however, any significant effects of the LAC lesion on
PV+ neurons in the SNr in either the sham group or the LAC
group, 1 week following surgery (Figure 1F, Table 1).
Intranigral Injection of LAC Causes Accumulation
of α-Synuclein and S129-P α-synuclein
Immunohistochemistry revealed that intranigral administration
of LAC led to an increase in α-synuclein (Figures 2B,D) and
S129-P α-synuclein (Figures 2A,C) immunoreactivity at both 1
and 3 weeks post-lesion, with no signs of progression of pathol-
ogy between the two time points. Densitometric analyses revealed
an increase in α-synuclein immunoreactivity in the ipsilateral
SN with ∼50% [treatment factor: F(1, 12) = 40.20, p < 0.001],
that could be observed at both 1 week (p < 0.001) and 3
weeks (p < 0.05) post-lesion (Figure 2D, Table 1). Further-
more, we could document an increase in S129-P α-synuclein
immunoreactivity in the ipsilateral SN with ∼150% [treatment
factor: F(1, 12) = 13.23, p < 0.01], at both 1 week (p < 0.05)
and 3 weeks (p < 0.05) post-surgery (Figure 2C, Table 1).
The increased expression of α-synuclein and S129-P α-synuclein
could be observed throughout the entire rostro-caudal extent
of the SN, and did not affect neighboring regions, such as
the VTA (Supplementary Figure 1). Furthermore, the increased
immunoreactivity seemed to be observed mainly in the SNr,
where it presented as neuropil (Figures 2C,D). Confocal flu-
orescent double labeling experiments also indicated increased
S129-P α-synuclein expression in SNc neurons, as S129-P α-
synuclein was seen to accumulate in TH+ (Figure 3B) and
NeuN+ (Figure 3C) nigral neurons, but not GFAP+ astro-
cytes (Figure 3A). Accumulated S129-P α-synuclein showed both
nuclear (Figure 3B), and cytoplasmic (Figure 3C) subcellular
distribution.
Frontiers in Behavioral Neuroscience | www.frontiersin.org 5 March 2015 | Volume 9 | Article 68
Bentea et al. Nigral proteasome inhibition in mice
TABLE 1 | Neuropathological and neurochemical changes after 3µg LAC (or saline) infusion in the left SNc.
SHAM 1w LAC 1w SHAM 3w LAC 3w
Ipsi Contra Ipsi Contra Ipsi Contra Ipsi Contra
TH+ profiles
SNc
1071 ± 75.42 1175 ± 58.27 725 ± 29.74*** 1298 ± 65.26 995.2 ± 108.3 1077 ± 87.75 742.8 ± 108*** 1205 ± 69.67
TH+ profiles
VTA
1630 ± 143.5 1655 ± 180.5 1431 ± 182.8 1696 ± 41.52 1491 ± 179.7 1656 ± 107.7 1562 ± 254.2 1618 ± 255.1
TH+ profiles
PBP p.i.
226.4 ± 14.8 250.8 ± 24.5 159.2 ± 12.1* 258.2 ± 29.5 208.7 ± 20.2 232.7 ± 15.8 163.3 ± 15.5** 245.7 ± 21.6
PV+ profiles
SNr p.i.
565.2 ± 34.9 625.4 ± 41.6 529.5 ± 26.7 569.8 ± 47.2 – – – –
TH+ volume
SN (mm3 )
0.457 ± 0.015* 0.482 ± 0.017 0.367 ± 0.021** 0.452 ± 0.015 0.398 ± 0.024 0.406 ± 0.022 0.320 ± 0.014*** 0.421 ± 0.017
α-synuclein
SN OD
1.04E-3 ± 1.9E-4 1.02E-3 ± 1.2E-4 2.53E-3 ± 3.6E-4* 1.56E-3 ± 2.5E-4 1.91E-3 ± 1.7E-4 1.75E-3 ± 2.2E-4 3.23E-3 ± 5.3E-4* 2.22E-3 ± 2.9E-4
α-synuclein
S129-P SN
OD
2.96E-3 ± 2.4E-4 2.83E-3 ± 2.2E-4 4.39E-3 ± 8.3E-4** 1.83E-3 ± 5.9E-4 2.64E-3 ± 5.8E-4 2.48E-3 ± 4.9E-4 3.59E-3 ± 6.7E-4** 1.64E-3 ± 4.9E-4
DA (ng/g)
striatum
13681 ± 1219 12875 ± 1014 9405 ± 1219*** 15089 ± 1132 15460 ± 429 15746 ± 1435 9302 ± 1639*** 15838 ± 1321
DOPAC (ng/g)
striatum
1503 ± 252.0 1760 ± 399.3 957.4 ± 108.1** 1361 ± 119.2 1255 ± 65.66 1312 ± 90.80 1238 ± 309.5 1925 ± 436.1
DOPAC/DA
striatum
0.125 ± 0.034 0.151 ± 0.044 0.107 ± 0.013 0.091 ± 0.007 0.081 ± 0.005 0.087 ± 0.009 0.169 ± 0.050 0.138 ± 0.042
Data are presented as mean ± s.e.m., and were analyzed using a paired t-test, comparing variables from left and right brain structures of the same mouse (***p < 0.001, **p < 0.01,
*p < 0.05). DA, dopamine; DOPAC, 3,4-dihydroxyphenylacetic acid; LAC, lactacystin; PV, parvalbumin; SN, substantia nigra; SNc, substantia nigra pars compacta; SNr, substantia
nigra pars reticulata; TH, tyrosine hydroxylase; VTA, ventral tegmental area (p.i., peri-injection; OD, optical density, calculated as described in Materials and Methods).
FIGURE 1 | Significant degeneration of the nigrostriatal DA-ergic
pathway in mice receiving 3µg LAC. TH immunohistochemistry
revealed a significant loss of TH+ profiles in the SNc (A,E), as well
as in the PBP located at the injection site (B,E), following LAC
administration. Loss of nigral TH+ profiles translated to reduced striatal
DA content (C). LAC lesion also caused a slight atrophy (D) and
deafferentation of the ipsilateral SN (asterisk in E), but did not damage
GABA-ergic neurons in the SNr at the injection site (as evaluated
using PV immunohistochemistry, F). Data are presented as percentage
decrease in TH+ profiles (A,B), DA content (C), or TH+ SN volume
(D) compared to the intact side (mean ± s.e.m.). ***p < 0.001
(Two-Way ANOVA), ###p < 0.001, ##p < 0.01, #p < 0.05
(Bonferroni post-hoc vs. sham). Sample size indicated in the figure.
DA dopamine, LAC lactacystin, PBP parabrachial pigmented nucleus,
SN substantia nigra, SNc substantia nigra pars compacta, TH tyrosine
hydroxylase. Scale bar 400µm (E,F).
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FIGURE 2 | Accumulation of α-synuclein and S129-P α-synuclein
in the SN of mice receiving 3µg LAC. Immunohistochemical
analyses revealed an increase in S129-P α-synuclein (A,C) and
α-synuclein (B,D) immunoreactivity in the SN of LAC-treated mice.
High magnification photomicrographs of the ipsilateral SNr in (A,B)
demonstrate the presence of S129-P α-synuclein and α-synuclein
immunoreactive fibers (C,D respectively). Data are presented as
percentage increase in S129-P α-synuclein (C) or α-synuclein (D)
optical density compared to the intact side (mean ± s.e.m.).
***p < 0.001, **p < 0.01 (Two-Way ANOVA), ###p < 0.001,
#p < 0.05 (Bonferroni post-hoc vs. sham). Sample size indicated in
the figure. LAC lactacystin, OD optical density, S129-P
S129-phosphorylated, SN substantia nigra. Scale bar 400µm (A,B),
50µm (C,D).
LAC-Treated Mice Develop Parkinsonian Motor
and Non-Motor Features
For all behavioral tests described, Two-Way ANOVA failed to
reveal any interaction effect between time and lesion, indicat-
ing a stable and non-progressive behavioral phenotype between
1 and 3 weeks. Furthermore, all behavioral tests were conducted
in a drug-free state, which is believed to give a natural and rele-
vant behavioral outcome in models of nigrostriatal degeneration
(Cenci et al., 2002; Glajch et al., 2012).
First, we investigated the effect of the LAC lesion on motor
function, using the accelerating rotarod task, a classical test used
to assess motor coordination and balance in rodents bearing
DA lesions. This paradigm is also believed to give indications
of bradykinesia and/or limb rigidity, as the accelerating protocol
requires fast and continuous adaptation of the mouse to increas-
ing rod speeds (Sedelis et al., 2001). No significant differences
could be observed in baseline performance in the training phase
between groups (Supplementary Figure 2). After surgery, LAC-
treated mice demonstrated decreased rotarod performance when
compared to sham mice [treatment factor: F(1, 56) = 31.15,
p < 0.001], an effect that could be significantly observed at
both 1 week (p < 0.01) and 3 weeks (p < 0.001) post-lesion
(Figure 4A).
Next, we employed the cylinder test to investigate forelimb
asymmetry, and revealed that LAC-treated mice had a signifi-
cant decrease in the use of the contralateral paw for performing
weight-bearing supporting touches while exploring the cylinder
walls [treatment factor: F(1, 42) = 18.70, p < 0.001]. This small,
but significant effect could be observed at both 1 week (p < 0.05)
and 3 weeks (p < 0.01) after lesion, indicating contralateral
forelimb akinesia (Figure 4B). Moreover, blinded investigation
of cylinder test video recordings revealed that LAC-treated mice
showed an increased preference to scan the cylinder walls using
the ipsilateral side of the body [treatment factor: F(1, 45) = 25.26,
p < 0.001] (Figure 4C), that was seen to significantly occur at
both 1 week (p < 0.05) and 3 weeks (p < 0.001) post-lesion.
Using the adhesive removal test, we investigated the effect
of LAC lesion on sensorimotor function. Baseline performance
demonstrated no significant differences in the training phase
between groups (Supplementary Figure 2). After lesion, we
could notice a global increase in time-to-contact [treatment
factor: F(1, 29) = 7.58, p < 0.05] (Figure 4D), indicating
a slightly decreased sensitivity to tactile stimuli. The adhesive
removal results also demonstrated a global impairment of skilled
and coordinated forelimb use [treatment factor: remove-contact,
F(1, 29) = 7.12, p < 0.05], that seemed to be particularly visi-
ble at 1 week post-lesion (p < 0.05). This impairment affected
the contralateral paw (Figure 4E), with no significant differ-
ences observed in the performance of the ipsilateral paw (data
not shown), indicating a specific effect of the unilateral LAC
lesion on skilled forelimb use and/or motivation to remove the
adhesive.
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FIGURE 3 | Accumulation of S129-P α-synuclein in SNc neurons
of mice receiving 3µg LAC. Immunofluorescence analyses
demonstrate accumulation of S129-P α-synuclein in nigral TH+ (B)
and NeuN+ (C) neurons, but not GFAP+ astrocytes (A). GFAP, glial
fibrillary acidic protein; NeuN, neuronal nuclei; TH, tyrosine hydroxylase.
Scale bar 10µm.
To gain more insight into the effect of LAC on skilled fore-
limb performance, we employed the nest building test. After LAC
lesion, we could observe a slight and global decrease in the nest
score when compared to sham-treated mice [treatment factor:
F(1, 29) = 4.98, p < 0.05] (Figure 4F). This effect was also
observed when weighing the amount of nesting material shred-
ded overnight, as a semi-independent objective assay of nesting
ability [treatment factor: F(1, 29)= 4.36, p < 0.05] (Figure 4G).
In order to evaluate spontaneous activity, we employed
the open-field test. Surprisingly, the results revealed a general
hyperkinetic behavior when integrating both distance traveled
[treatment factor: F(1, 56) = 7.22, p < 0.01] (Figure 5A) and
velocity [treatment factor: F(1, 56) = 7.21, p < 0.01] (Figure 5B),
that was especially visible 3 weeks post-surgery (p < 0.01).
The observed hyperactive behavior could be due to the devel-
opment of akathisia after lesion, a feature that also occurs in
early PD patients (Gjerstad et al., 2011). Indeed, we noticed
increased restlessness of LAC-treatedmice during the tail suspen-
sion test. While sham-treated mice exhibited a normal behavior
during the tail suspension test, with periods of immobility after
the initial struggle to escape (Supplementary Video 1, showing
a representative 1min interval of the tail suspension test starting
at 2min and 30 s into the test), LAC-treated mice demonstrated
continuous movement/restlessness during the same period of
time (Supplementary Video 2 for minor akathisia-like behav-
ior, Supplementary Video 3 for strong akathisia-like behavior).
As such, development of akathisia could have masked potential
bradykinetic effects of LAC on behavior in the open-field test.
Also in the open-field test we could observe an increased ipsi-
lateral thigmotactic behavior after blinded integration of the first
5min of the trial. LAC lesion led to an increased preference to
scan the open-field walls using the ipsilateral side of the body
[treatment factor: F(1, 56) = 11.46, p < 0.01] (Figure 5C), at
both 1 week (p < 0.05) and 3 weeks (p < 0.05) post-lesion.
Finally, analysis of open-field data revealed that LAC-treated
mice demonstrate global and slight decreases in turn angle [treat-
ment factor: F(1, 56) = 13.58, p < 0.001] (Figure 5D), as well
as in meander [treatment factor: F(1, 56) = 7.32, p < 0.01]
(Figure 5E), that were particularly evident 3 weeks post-lesion
(p < 0.01 for turn angle, and p < 0.05 for meander). These
results indicate that lesionedmice tended to followmore straight,
repetitive motor sequences, with decreased turning behavior
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FIGURE 4 | Motor and somatosensory impairment in mice receiving
3µg LAC. In the accelerating rotarod test, LAC lesioned mice showed
decreased time spent on the rod, compared to sham mice receiving
vehicle (A). In the cylinder test, LAC-treated mice engaged in significantly
less right paw wall-contacts compared to sham mice (B). Also,
LAC-treated mice had an increased preference to scan the cylinder walls
more with their intact ipsilateral side (C). In the adhesive removal test,
both time-to-contact (D), and the time required to remove the adhesive
after detection (time-to-remove—time-to-contact) (E), were globally
increased after LAC treatment compared to sham mice. Furthermore, in
the nest building test, the nest score (F), as well as the amount of
nesting material shredded (G), were globally decreased after LAC lesion,
compared to sham mice. Data are presented as mean ± s.e.m.
*p < 0.05, ***p < 0.001 (TwO-Way ANOVA), #p < 0.05, ##p < 0.01,
###p < 0.001 (Bonferroni post-hoc vs. sham). Sample size indicated in
the figure. LAC lactacystin.
(Figures 5G,H). Interestingly, performing linear regression anal-
ysis with data from all experimental groups showed that meander
was inversely correlated with velocity in the open-field, high-
lighting that perseverative behavior and hyperkinesia are closely
related and potentially inter-connected as behavioral phenotypes
following LAC (Figure 5I).
Depression and anxiety are highly relevant parkinsonian non-
motor symptoms, and important determinants for the quality of
life in PD (Martinez-Martin, 2011). Analysis of the time spent
in the center of the open-field arena revealed that LAC lesion
induced a slight and global decrease in the time spent in cen-
ter [treatment factor: F(1, 56) = 4.08, p < 0.05] (Figure 5F). In
the light/dark test, LAC lesion led to a global increase in latency
to exit the shelter [treatment factor: F(1, 28) = 6.44, p < 0.05]
(Figure 6B), but did not influence the time spent outside the shel-
ter [treatment factor: F(1, 28) = 2.25, p > 0.05] (Figure 6A).
These changes occurred in the absence of any effect on motor
behavior, as open-field video tracking of the mouse while outside
the shelter failed to reveal any significant changes in velocity (data
not shown). The significant effect of LAC lesion on the latency
to exit the shelter, but not the time spent outside the shelter was
intriguing, and we hypothesized that the observed effects could
also reflect perseverative thigmotaxis. Indeed, we could notice a
significant inverse correlation between latency to exit the shelter
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FIGURE 5 | Spontaneous behavior of mice treated with 3µg LAC as
observed in a 60min open-field test. Distance traveled (A), and
velocity (B) were globally increased in LAC lesioned mice, compared to
sham mice receiving vehicle. Furthermore, mice treated with LAC had
significantly increased ipsilateral scanning behavior (C). LAC lesion also
induced global decreases in turn angle (D), as well as in meander (E).
This perseverative behavior is reflected in representative 10min
trajectories of a sham-treated (G), and a LAC-treated (H) mouse at 3
weeks post-surgery. Linear regression analysis performed with data from
all experimental groups revealed a close inverse correlation between
meander (perseverative behavior) and velocity (hyperkinesia) (I). LAC
lesion induced a global reduction in time spent in the center of the arena,
compared to sham mice (F). Data are presented as mean ± s.e.m.
*p < 0.05, **p < 0.01, ***p < 0.001 (Two-Way ANOVA), #p < 0.05,
##p < 0.01 (Bonferroni post-hoc vs. sham). Sample size indicated in the
figure. LAC lactacystin.
and meander in the open-field (Figure 6C), indicating that the
increased latency to exit the shelter can be due to perseverative
behavior causing decreased alternations between the two com-
partments of the open-field. Perseverative thigmotaxis could have
also manifested in the open-field test, leading to a global decrease
in time spent in center.
Finally, we investigated the effect of LAC administration on
development of depressive-like symptoms using the mouse tail
suspension test. Interestingly, in sharp contrast to previous find-
ings in the literature (Drui et al., 2014), we could observe a global,
paradoxical decrease in immobility time after LAC [treatment
factor: F(1, 26) = 11.83, p < 0.01] (Figure 6D) that seemed to
be especially evident at 1 week post-lesion (p < 0.01). However,
several factors might have biased the interpretation of this test.
First, the development of a hyperkinetic behavior and restlessness
after LAC lesion could have confounded the effect on immobility
time. Furthermore, the increased perseverative behavior docu-
mented after LAC could also influence the interpretation of the
results, as the mice might have shown increased escape-oriented
behavior due to cognitive vs. depressive-like behavioral differ-
ences. This is consistent with a significant correlation that we
could find between immobility time in the tail suspension test
and meander in the open-field test, highlighting that increased
perseverative behavior can decrease immobility time in the tail
suspension test (Figure 6F).
We have also used the tail suspension test as a platform
to study motor asymmetry upon engaging in escape-oriented
behaviors. Blinded analysis of the first minute from the tail
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FIGURE 6 | The light/dark and tail suspension tests in mice receiving
3µg LAC. Although the time spent outside the shelter in the light/dark
paradigm was not significantly affected (A), LAC lesion led to a global
increase in the latency to exit the shelter compared to sham mice receiving
vehicle (B). The tail suspension test revealed that LAC-treated mice had
decreased periods of immobility, compared to sham mice (D). Linear
regression analysis performed with data from all experimental groups
revealed that perseverative behavior (meander) correlates with latency to exit
the shelter (C), as well as with the immobility time in the tail suspension tests
(F). Mice treated with LAC also demonstrated significantly increased
ipsilateral body swings compared to sham mice during their escape-oriented
behavior (E). Data are presented as mean ± s.e.m. *p < 0.05, **p < 0.01
(Two-Way ANOVA), ##p < 0.01 (Bonferroni post-hoc vs. sham). Sample
size indicated in the figure. LAC lactacystin.
suspension video tracks revealed that LAC lesion led to a
global increase in contralateral body swings [treatment factor:
F(1, 26) = 13.61, p < 0.01] (Figure 6E), an effect especially visible
at 1 week post-surgery (p < 0.01), confirming motor asymmetry
following lesion.
Discussion
Despite important advances in our understanding of the molec-
ular pathogenesis and symptomatology of PD, there is still an
urgent need for new developments, especially concerning transla-
tion of successful neuroprotective findings from pre-clinical ani-
mal studies to the clinic (Kieburtz and Olanow, 2007). Failure to
achieve clinical translation might stem from various reasons, but
it has been hypothesized that one could be the limited diversity of
animal models used (Jenner, 2008; Duty and Jenner, 2011; Dex-
ter and Jenner, 2013). Indeed, the molecular pathways relevant
for PD pathogenesis are numerous and highly inter-connected,
and include oxidative stress, mitochondrial dysfunction, protein
aggregation, failure of protein degradation systems, neuroinflam-
mation, and glutamate excitotoxicity (Dexter and Jenner, 2013;
Lim and Zhang, 2013). Therefore, animal models mimicking any
of these pathogenic pathways leading to DA-ergic neurodegen-
eration are highly relevant in terms of construct validity, and
should probably be used in a combinatorial manner in pre-
clinical drug development (Dawson et al., 2002). Furthermore,
although α-synuclein pathology is a central feature in PD, it has
not been consistently reproduced in classic toxin-basedmodels of
PD, such as the 6-hydroxydopamine (6-OHDA) orMPTPmodels
(Dexter and Jenner, 2013). Although viral vector-based models
overexpressing α-synuclein in the SN of rats or mice have been
developed that display α-synuclein aggregation and dopaminer-
gic cell death (Lauwers et al., 2007; Oliveras-Salva et al., 2013; Van
der Perren et al., 2015), there is still an important need for the
characterization of novel models of sporadic PD, with different
mechanisms of action and good construct, face, and predictive
validity (Duty and Jenner, 2011).
Recently, a contribution of proteasomal impairment to the
protein aggregation and neurodegeneration associated with PD
has been proposed (Olanow and McNaught, 2006; Lim, 2007;
Ebrahimi-Fakhari et al., 2012). Post-mortem data obtained from
sporadic PD indicated structural and functional defects in
the 26/20S proteasome, including loss of 20S core α-subunits
(McNaught et al., 2002a; Grunblatt et al., 2004; Bukhatwa et al.,
2010), loss of 19S regulatory particles, including the proteasomal
activator PA700 (McNaught et al., 2003; Grunblatt et al., 2004),
as well as a general loss of all three peptidase activities of the 20S
proteasome (McNaught and Jenner, 2001; Tofaris et al., 2003).
In the brain, the proteasome seems to be specifically inhibited in
the SNc, with sparing of proteasome function in other areas such
as the striatum, or cortex, where neuronal loss is not observed
(Furukawa et al., 2002;McNaught et al., 2003; Tofaris et al., 2003).
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Testing the proteasomal inhibition hypothesis of neurodegen-
eration in vivo requires the use of a highly specific and potent
inhibitor that can inhibit all three peptidase activities of the pro-
teasome, but does not affect other proteases or degradation path-
ways of the cell. This can be achieved using LAC, a Streptomyces
natural product (Fenteany and Schreiber, 1998). Local adminis-
tration of LAC to the nigrostriatal pathway has been previously
shown to cause DA-ergic neurodegeneration when applied to the
SNc of rats (McNaught et al., 2002b; Vernon et al., 2010; Mackey
et al., 2013; Pienaar et al., 2015) or the medial forebrain bundle of
mice (Xie et al., 2010).
In order to further describe the proteasome inhibition model
of PD, we stereotaxically injected 3µg LAC to the left SNc of
mice. Our results demonstrated an acute loss of TH+ profiles
in the injected SNc compared to the contralateral SNc of ∼40%,
that did not progress between 1 and 3 weeks post-surgery. In
comparison to nigral neurons, neighboring VTA DA-ergic neu-
rons did not seem to be significantly affected, when counted over
the entire rostro-caudal extent. This particular resistance of VTA
DA-ergic neurons to LAC-induced toxicity is in line with previ-
ous observations in LAC models (Xie et al., 2010; Mackey et al.,
2013), and could be linked to the increased resilience of these
DA-ergic neurons to toxic stimuli (Brichta and Greengard, 2014).
Indeed, in a recent study, Subramaniam et al. demonstrated that
direct infusion of proteasome inhibitor epoxomicin in the VTA
of mice did not cause loss of VTA TH+ neurons, further hinting
at a resistance of these neurons to proteasomal-induced cell death
(Subramaniam et al., 2014). At the same time, however, Vernon
et al. reported that after intranigral LAC administration, VTA
DA-ergic neurons are not free of toxicity especially around the
injection tract (Vernon et al., 2010). Therefore, we specifically re-
evaluated the lateral part of the VTA, the PBP, at the level of the
injection site. We chose to focus on this region for two important
reasons: (i) it is located the closest to the injection coordinates,
and (ii) it is the region of the VTA which is particularly affected
in PD (McRitchie et al., 1997), indicating a potential vulnerability
of this A10 cell subgroup to neurodegeneration. We found that
LAC administration did damage this subset of neurons, leading
to a loss of about 30% compared to the contralateral side, at both
1 and 3 weeks post-lesion. This effect was however not observed
anymore when counting the entire rostro-caudal VTA, indicating
a local effect of the lesion on the anterior PBP at the injection site.
Loss of nigral DA-ergic neurons translated to a significant
loss of ∼40% striatal DA, that did not progress between 1 and 3
weeks post-surgery. We did not detect any significant changes in
DOPAC/DA ratio in the ipsilateral striatum after LAC. Increased
DA turnover in the caudate/putamen is believed to be one of
the functional compensatory changes occurring in PD (Pifl and
Hornykiewicz, 2006), that maintains normal motor function
until a threshold of ∼80% DA depletion is reached. The obser-
vation that no changes in DA turnover occurred after intranigral
LAC indicates the presence of an acute neurodegenerative pro-
cess that occurred in the absence of functional compensation.
The acute and non-progressive nature of the lesion is in line with
previous reports of intranigral toxin models, such as the intran-
igral 6-OHDA rat model (Jeon et al., 1995) and the intranigral
LAC rat model (Mackey et al., 2013), and might be related to a
direct effect of the toxin on nigral DA-ergic cell bodies.
Stereological analysis of the TH+ ipsilateral SN volume
revealed a significant shrinkage in volume of the SN after LAC
lesion. A similar loss of planimetric (regional) volume of the
TH+ ipsilateral SN, ∼20% vs. the contralateral side, has been
recently reported after moderate unilateral DA depletion induced
by intrastriatal 6-OHDA in rats (Healy-Stoffel et al., 2014). Fur-
thermore, our findings are in line with MRI findings document-
ing a decrease in the volume of the ipsilateral midbrain after
administration of LAC to the SNc (Vernon et al., 2010) or the
medial forebrain bundle (Vernon et al., 2011), as well as with the
observation of decreased SN volume in PD patients (Sako et al.,
2014). As the decrease in volume in our case did not seem to
occur with loss of GABA-ergic neurons in the SNr, it is tempting
to hypothesize that it might have resulted from secondary mor-
phological changes, such as the deafferentation of the ipsilateral
SNr due to loss of nigral DA-ergic dendrites.
Mechanistic studies demonstrated that LAC leads to DA-ergic
cell death via apoptosis mediated by various upstream factors
including reactive oxygen species (Perez-Alvarez et al., 2009), dis-
turbance of iron (Vernon et al., 2010; Li et al., 2012; Le, 2014) and
calcium (Li et al., 2007) homeostasis, and accumulation of p53
(Nair et al., 2006). LAC might also induce DA-ergic cell death, at
least partly, by increasing the expression of S129-P α-synuclein, a
post-translational modification present in ∼90% of α-synuclein
in Lewy bodies (Fujiwara et al., 2002; Anderson et al., 2006).
Although the precise contribution of S129-P α-synuclein to the
pathogenesis of PD remains to be elucidated (Tenreiro et al.,
2014), this modification has recently been shown to enhance DA-
ergic neurodegeneration in a rat model of familial PD (Sato et al.,
2011), providing clues to a potential toxic gain-of-function. This
is in line with the observation that S129-P α-synuclein expression
increases progressively and concomitantly with the neurode-
generative degree in mice overexpressing α-synuclein (Oliveras-
Salva et al., 2013).While accumulation of proteins such as S129-P
α-synuclein, might be expected to cause toxicity, sub-lethal doses
of proteasomal inhibitors given in combination with MPP+,
rotenone, or 6-OHDA enhance the formation of α-synuclein pos-
itive inclusions, and surprisingly protect against neuronal death
induced by either of the three toxins (Sawada et al., 2004; Inden
et al., 2005). These findings support a role for low-level pro-
teasomal inhibition in neuroprotection, potentially by allowing
the formation of larger α-synuclein aggregates, which might be
less toxic compared to smaller oligomeric species (Tanaka et al.,
2004; Inden et al., 2005). In contrast, higher and toxic doses of
proteasomal inhibitors exacerbate cell death induced by MPP+,
rotenone, or 6-OHDA (Hoglinger et al., 2003), suggesting that
the level of inhibition of the proteasome activity might dictate
neuroprotection vs. enhanced cell death following toxic stim-
uli. In the current study, we observed that intranigral protea-
somal inhibition in mice leads to increased S129-P α-synuclein
immunoreactivity in the ipsilateral SN. This was accompanied
by a similar increase in total levels of unmodified α-synuclein,
consistent with previous findings indicating that unmodified α-
synuclein is a substrate of the proteasome (Tofaris et al., 2001;
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Ebrahimi-Fakhari et al., 2011). Taking into account the afore-
mentioned observations, it is difficult to resolve in our set-up
whether α-synuclein and S129-P α-synuclein accumulation plays
a toxic or protective role in LAC-induced DA-ergic cell death, or
is simply an epiphenomenon following the lesion. Future inves-
tigations in this direction would be particularly informative in
revealing the complex relationship between proteasomal inhi-
bition, accumulation of α-synuclein, and DA-ergic cell death.
Moreover, due to the general increase in α-synuclein, we cannot
exclude that the increased expression of S129-P α-synuclein was
simply due to accumulation of substrate available for phospho-
rylation. At the same time, however, Machiya et al. previously
reported a specific increase in S129-P α-synuclein after protea-
somal inhibition in the absence of changes in the total amount
of α-synuclein, suggesting that S129-P α-synuclein is on its own
a substrate for proteasomal degradation (Machiya et al., 2010).
As such, the increased expression of S129-P α-synuclein in our
case might be the combined result of impaired degradation of the
phosphorylated protein and accumulation of substrate available
for phosphorylation.
Increased immunoreactivity of α-synuclein and S129-P α-
synuclein in immunohistochemistry was observed mainly in the
SNr, where it presented as neuropil. Interestingly, Miwa et al.
reported a similar distribution of increased expression of α-
synuclein in nerve terminals in the SNr following intrastriatal
administration of LAC to rats (Miwa et al., 2005). The authors
suggested that this increase could be due to accumulation of
α-synuclein in striatonigral terminals in the SNr (Miwa et al.,
2005). In accordance, the observed effect at the level of the SNr
after intranigral LAC might be due to an increase in α-synuclein
and S129-P α-synuclein expression in nerve terminals project-
ing to the SNr. Furthermore, immunofluorescence analysis of the
SNc revealed accumulation of S129-P α-synuclein in nigral neu-
rons. Increased expression of S129-P α-synuclein was detected in
TH+ and NeuN+ neurons, but not in GFAP+ astrocytes, high-
lighting a preferential effect of LAC in disrupting α-synuclein
homeostasis in neurons. This is consistent with recent findings
indicating that neurons have a lower proteasome activity com-
pared to glial cells, and therefore are more vulnerable to protein
accumulation (Tydlacka et al., 2008). It is noteworthy that we
could also detect accumulation of S129-P α-synuclein in TH-
neurons (data not shown). This is most likely the result of the
indiscriminate mechanism of cell entry of the active metabo-
lite of LAC (clasto-lactacystin β-lactone) that gains access to the
20S proteasome via passive diffusion through the cell membrane
(Dick et al., 1997). In a similar manner, LAC was found to lead
to formation of ubiquitin- and α-synuclein-positive inclusions
in both TH+ and TH- neurons in rat ventral midbrain cul-
tures (Rideout et al., 2005). Interestingly, accumulated S129-P
α-synuclein had both cytoplasmic and nuclear distribution. The
subcellular localization of α-synuclein is known to be mediated
by S129 phosphorylation, with various kinases modulating the
bi-directional shuttling of α-synuclein between nuclear and cyto-
plasmic compartments (Goncalves and Outeiro, 2013). Our find-
ings of nuclear localization of S129-P α-synuclein are consistent
with the observed nuclear distribution of S129-P α-synuclein in
the SN of α-synuclein transgenic mice (Wakamatsu et al., 2007).
Several behavioral paradigms have been used to characterize
motor and non-motor impairment in our model. Overall, mice
injected intranigrally with LAC demonstrated PD-like motor
behavioral impairment, consistent with previous studies inves-
tigating the effect of LAC lesions in rats (Vernon et al., 2010,
2011; Mackey et al., 2013; Konieczny et al., 2014; Pienaar et al.,
2015), and mice (Xie et al., 2010). Both rotarod and cylinder
tests revealed a significant decrease in motor performance in
LAC-treated mice, reflecting impaired coordination and balance,
bradykinesia, and contralateral forelimb akinesia. In the adhesive
removal test, LAC lesion induced a general delay in the removal
of the adhesive after contact, an effect that was especially visible
at 1 week post-surgery. This impairment could reflect impaired
skilled and coordinated movement, however it could also result
from decreased motivation to remove the adhesive. The nest
building test indicated amodest and global effect on the quality of
the nest, as well as on the amount of nesting material shredded,
demonstrating a slightly decreased capacity of the LAC mice to
create a nest. This in turn, could be a consequence of decreased
skilled forelimb use, however, similar as for the adhesive removal
test, motivational aspects cannot be completely dissociated.
Besides motor symptoms, non-motor symptoms are increas-
ingly recognized to be present and to have a very important
impact on the quality of life of PD patients (Chaudhuri and
Schapira, 2009). As non-motor symptoms are increasingly rec-
ognized in PD, there is a current need for their characteriza-
tion in animal models (Dunnett and Lelos, 2010; Taylor et al.,
2010). Although proteasome inhibition models have been shown
to develop motor impairment, no studies were performed so far
studying non-motor symptoms.
In order to address this issue, we first assessed the sensitive
and somatosensory functions, as they are also affected in the
human condition (Conte et al., 2013; Patel et al., 2014). In the
adhesive removal test, we could observe a slightly decreased tac-
tile sensitivity following LAC lesion, potentially indicating altered
tactile sensory processing. Furthermore, evaluation of thigmotac-
tic scanning behavior in the open-field and cylinder tests indi-
cated that LAC lesion led to an increased preference to scan
different enclosure walls using the ipsilateral intact side of the
body. Increased ipsilateral thigmotactic scanning behavior has
been documented in models of unilateral DA depletion (Steiner
et al., 1988; Fornaguera et al., 1993), and is believed to reflect
decreased responsiveness to sensory stimuli on the side of the
body contralateral to the lesion (Huston et al., 1990). Alterna-
tively, the increased ipsilateral scanning behavior might have
resulted from spontaneous contralateral turning asymmetry after
lesion. Interestingly, it was recently demonstrated that intran-
igral epoxomicin administration in mice leads to contralateral
turning asymmetry, potentially linked with a hyperactive pheno-
type of the surviving DA neurons (Subramaniam et al., 2014).
While it is difficult to resolve in the current set-up whether the
increased thigmotactic scanning is purely linked with somatosen-
sory disturbances (such as decreased somatosensory perception
in the vibrissae contralateral to the lesion, Huston et al., 1990), the
observation that LAC-treated mice show contralateral sponta-
neous turning in the center of the open-field arena, thereby with-
out direct contact to the arena walls (unpublished observations),
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supports the view that it might arise at least partially as a result of
an hyperactive phenotype of the surviving DA neurons. Further-
more, intranigral LAC injection resulted in a global hyperkinetic
behavior, as observed in the open-field test, an effect especially
visible at 3 weeks post-surgery. The surprising hyperactive behav-
ior, also observed in the MPTP mouse model (Wang et al., 2013),
might indicate akathisia, a sensory disturbance inducing a gen-
eral restlessness, with a continuous urge tomove, but of unknown
pathophysiology (Patel et al., 2014). While akathisia seems to be
present in PD (Lang and Johnson, 1987; Comella and Goetz,
1994; Gjerstad et al., 2011) and linked with disturbed DA-ergic
transmission (Patel et al., 2014), this sensory disturbance, as well
as the mechanisms associated, have not been fully explored in
animal models. Interestingly, we could observe that LAC-treated
mice exhibited increased restlessness during a period of the tail
suspension test in which control mice demonstrate immobil-
ity, implying a possible development of akathisia-like behavior
following LAC.
Impairments in cognitive flexibility are recognized as part of
the executive dysfunction symptoms associated with early PD
(Cools et al., 2001; Pagonabarraga and Kulisevsky, 2012). Deficits
in set shifting (Cools et al., 2001), as well as an increased per-
severative behavior (Ebersbach et al., 1994) have been reported
to occur in early phases of PD. These cognitive impairments
could have a strong impact on the quality of life as deficits in
set shifting are strongly associated with freezing of gait (Nai-
smith et al., 2010). Interestingly, LAC-treated mice demonstrated
a global increase in perseverative behavior in the open-field,
an effect especially visible 3 weeks post-surgery. The decreases
in turn angle and meander indicated that lesioned mice gener-
ated less random movement, and tended to follow more straight
sequences. These results are consistent with the modulating role
played by striatal DA in controlling cognitive flexibility (Costa
et al., 2014; Darvas et al., 2014).
Furthermore, the perseverative behavior was strongly man-
ifested in our model, as it influenced the evaluation of mice
in the anxiety- and depression-based paradigms. Indeed, in the
light/dark test lesioned mice had an increase in the latency to
exit the shelter that occurred in absence of changes in time
spent outside the shelter. Together with a significant correla-
tion with meander as measure of perseverative behavior, the
increased latency to exit the shelter can be partly attributed to
a decrease in alternations between the two compartments of the
open-field due to perseverative thigmotaxis. Concomitantly, in
the tail suspension test we could notice that LAC lesion led to
a surprising global decrease in immobility time, an effect espe-
cially visible at 1 week post-surgery. These results are in sharp
contrast to literature findings that indicate a depressive-like phe-
notype following nigrostriatal DA-ergic neurodegeneration (Drui
et al., 2014). However, we could observe a significant associ-
ation between immobility time in the tail suspension test and
meander as measure of perseverative behavior, indicating that
the decrease in immobility of the LAC-treated mice can be due
to increased perseverance to engage in escape-oriented behav-
iors. Our results thus highlight that cognitive impairment can
confound measures of depressive-like symptoms in “behavioral
despair” paradigms. Due to the strong influence of persevera-
tive behavior on non-motor phenotypes related to anxiety and
depression, we believe that the intranigral LAC model is particu-
lar suited to study loss of cognitive flexibility in PD. At the same
time, we cannot completely dissociate a pure anxiogenic effect of
the LAC lesion that might have occurred in addition to changes
in cognitive behavior.
It would be interesting to speculate on the cause of the
observed non-motor behaviors, especially taking into account the
partial DA-ergic lesion induced by LAC. Partial damage to the
nigrostriatal DA-ergic pathway has been linked with the devel-
opment of somatosensory dysfunction (Fornaguera et al., 1993),
loss of cognitive flexibility (Darvas et al., 2014), and develop-
ment of anxiety-like behavior (Drui et al., 2014), phenotypes
which we document in our model. Furthermore, besides nigral
cell loss, we observed a localized loss of VTA DA-ergic neurons
situated in the PBP at the injection site. It is conceivable that
even a partial loss of TH+ neurons in the VTA could have con-
tributed, to a certain extent, to the observed non-motor behav-
iors. Consistent with such a view are observations indicating
that partial VTA lesions can induce perseverative behavior (Pioli
et al., 2008), hyperactivity (Koob et al., 1981), and contribute to
sensorimotor neglect developed after a nigrostriatal lesion (Lees
et al., 1985). Additionally, damage to non-DA-ergic systems fol-
lowing LAC could have influenced some of the observed non-
motor features. Indeed, compared to other PD toxins that show
specificity for DA-ergic neurons (such as 6-OHDA), the active
metabolite of LAC diffuses freely through cell membranes (Dick
et al., 1997), although DA-ergic neurons might be particularly
sensitive to proteasome-inhibition mediated cell death (Petru-
celli et al., 2002; however also see Reaney et al., 2006). In order
to evaluate possible non-specific damage of the lesion on sur-
rounding cell populations, we chose to focus on the GABA-ergic
neurons of the SNr in immediate proximity of the injection site.
Our findings indicate that intranigral LAC lesion did not signif-
icantly damage PV+ neurons in the SNr, supporting the notion
that GABA-ergic neurons are more resistant to proteasomal dys-
function than DA-ergic neurons (Rideout et al., 2005). Although
we exclude a potential influence of damage to the SNr on the
observed behavior, LAC injection might have also affected other
nuclei located in close proximity to the injection site (Vernon
et al., 2010), or that project to the SNc such as the pedunculo-
pontine nucleus (PPN). Indeed, it was recently demonstrated that
intranigral LAC administration in rats leads to a loss of choliner-
gic neurons in the PPN (Pienaar et al., 2015), similar as to the
loss observed in PD patients. Although not assessed in the cur-
rent study, we acknowledge that damage in extra-nigral areas,
such as the PPN, could have participated to the development of
non-motor symptoms in our model. For instance, PPN-lesioned
rats demonstrate difficulties in terminating a strongly selected
action (sucrose preference), potentially highlighting an increase
in perseverative behavior (Winn, 2006).
As a final characterization of our model, we evaluated asym-
metry in body swings during escape-oriented behavior. Indeed,
the elevated body swing test revealed that rats lesioned with 6-
OHDA have increased swing bias toward the side contralateral to
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the lesion, an effect that is sensitive even in conditions of moder-
ate DA depletion (Borlongan and Sanberg, 1995; Roghani et al.,
2002). Nevertheless, despite one earlier report in the literature
(Iancu et al., 2005), this test has not been fully evaluated in mouse
models of PD. The similarities in test set-up between the tail sus-
pension test and the elevated body swing test in mice (Iancu et al.,
2005), made us wonder whether we could use the tail suspension
video recordings to integrate body swing bias. Our results showed
a global increase in contralateral body swings in LAC lesioned
mice, confirming motor asymmetry. Furthermore, these findings
indicate that the tail suspension test can be combined with the
elevated body swing test for simultaneous phenotyping of motor
and non-motor features in unilateral models of PD, thereby
increasing the information density of the test (Gerlai, 2002), and
reducing the number of animals used (in line with the “Reduc-
tion” component of the 3Rs principle, Kilkenny et al., 2010).
In conclusion, we found that intranigral administration of
LAC to mice leads to nigrostriatal DA-ergic neurodegeneration
and accumulation of α-synuclein and S129-P α-synuclein. LAC
lesioned mice demonstrate motor impairment, as well as non-
motor features resembling early stage PD, including sensitive and
somatosensory alterations, anxiety-like behavior, and persevera-
tive behavior. At the same time, we acknowledge certain limita-
tions of the model with regard to translatability to the human
disorder. First, similar to other toxin-based models of PD, the
intranigral LAC model is characterized by an acute, and non-
progressive neurodegenerative process, that could be different
than the one occurring in a chronic neurodegenerative disorder
as PD (Duty and Jenner, 2011). Second, although the prefer-
ence of LAC to specifically induce DA-ergic neurodegeneration
has been previously documented in vitro (Petrucelli et al., 2002;
Mytilineou et al., 2004; Rideout et al., 2005), the indiscriminate
mechanism of cell entry LAC might cause non-specific damage
to neurons or glial cells, and should be carefully considered. Yet,
with taking these limitations into account, the model demon-
strates good construct and face validity, and represents an alter-
native platform to evaluate therapeutic strategies in PD, due to
its different, but relevant mechanism of inducing DA neuronal
loss. Furthermore, the characterization of the model in mice pro-
vides an advantage for subsequent application in transgenic mice,
in order to investigate molecular determinants of proteasomal
inhibition-induced neurodegeneration and validate therapeutic
targets.
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Supplementary Figure 1 | Rostro-caudal distribution of S129-P
α-synuclein (A) and α-synuclein (B) increased immunoreactivity through
the SN, following LAC administration. Increased expression of S129-P
α-synuclein and α-synuclein could be observed through the entire rostro-caudal
extent of the SN in mice unilaterally lesioned with LAC. Scale bar 400µm.
Supplementary Figure 2 | Baseline motor behavior in the rotarod and
adhesive removal tests. No significant differences could be observed in baseline
rotarod (A), and adhesive removal performance (B), indicating similar acquisition
of motor skilled behaviors between experimental groups. Data are presented as
mean ± s.e.m., p > 0.05 (One-Way ANOVA). Sample size indicated in the figure.
Supplementary Video 1 | “Behavioral despair” in the tail suspension test.
After a period of initial struggle, control mice demonstrate intervals of immobile
behavior, reflecting reluctance to maintain active escape-oriented behavior.
Indicated is a representative 1min interval from the tail suspension test of a
sham-treated mouse (trial period: 2min 30 s—3min 30 s), during which the
mouse shows primarily immobile behavior. The video is shown at 4x its normal
speed.
Supplementary Video 2 | Minor akathisia-like behavior in mice treated
with 3µg LAC. In comparison to sham mice, LAC-treated mice demonstrate less
immobile behavior and increased restlessness in the tail suspension test. Indicated
is a representative 1min interval from the tail suspension test of a LAC-treated
mouse (trial period: 2min 30 s—3min 30 s), during which the mouse shows minor
akathisia-like behavior (periods of continuous movement, combined with intervals
of immobility). The video is shown at 4x its normal speed.
Supplementary Video 3 | Strong akathisia-like behavior in mice treated
with 3µg LAC. In comparison to sham mice, LAC-treated mice demonstrate less
immobile behavior and increased restlessness in the tail suspension test. Indicated
is a representative 1min interval from the tail suspension test of a LAC-treated
mouse (trial period: 2min 30 s—3min 30 s), during which the mouse shows
strong akathisia-like behavior (continuous movement/restlessness). The video is
shown at 4x its normal speed.
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